enlightenbio  Blog

Category - M&As and partnerships

The Dangerous Bet Behind Big Pharma’s Silence

Why dismantling America’s biomedical innovation engine is a long-term threat to the very industry staying quiet about it. A recent piece by Steven Usdain, which was also highlighted by Holden Thorp, got me thinking: are...read more

Abbott to acquire Exact Sciences

• Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments•...read more

Tempus Announces the Acquisition of Paige

Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ: TEM), a technology company leading...read more